WP1: Establishment of traceability routes Current state of the art Not all NMI/DIs in Europe maintain primary standards of radioactivity Access to radioactivity standards in hospitals varies across Europe Clinical users reliant on non-traceable manufacturer supplied settings Low engagement between end-users and metrology communities. Beyond state of the Art (D1/D2) Establish traceability routes in partner countries for important radionuclides Create framework through guidance to expand networks internationally Engage with users to facilitate uptake WP2: Assessing Uncertainty Current state of the art No uncertainties = no traceability Unknown accuracy in administrations Unknown accuracy in activities derived from images and dosimetry calculations Low engagement of clinical community with metrology community Beyond state of the Art (D3/D4) Enable traceability routes to be created by incorporating uncertainties Determine current capability and highlight areas requiring improvement Engage with community to ensure uncertainties are a routine part of measurement WP3: Validation of effectiveness Current state of the art Comparison exercises in nuclear medicine not performed routinely Measurement capability in hospitals largely unknown across Europe Minimal guidance available on how to perform comparison exercises Beyond state of the Art (D1/D2) Perform comparisons to assess effectiveness of new calibration routes Create guidance to improve quality and quantity of comparison exercises performed in nuclear medicine. Deliver training and advice to end users on importance of traceability Enable future expansion of traceability WP4: Creating Impact Stakeholder and Industry Support Seven technical deliverables Communication and dissemination: Website, Newsletters, Social Media Stakeholder Committee, 4 workshops Engagement with societies & conferences Three guidance documents, at least two publications & training material Exploitation: Uptake of outputs by hospitals, equipment manufacturers, radiopharmaceutical industry… Upskilling the workforce through training Outcomes for Industry & others New calibration services available Protocols for establishing traceability Guidance on uncertainty estimation Facilitate CMC claims Standards and Compliance: Support compliance with regulations (EC Directives 2013/59/EURATOM, 2001/83/EC and 2001/20/EC) International uptake of outputs by IAEA, EANM, EFOMP & NM Societies Establish new networks & collaborations Long Term Impact Economic/technical: New calibration services from NMI/DIs creating traceability networks improving capability & harmonisation across Europe Improved accuracy of therapeutic and diagnostic administrations enabling pooling of data from multicentre clinical trials in NM Social: Accurate administrations and dosimetry in NM, improving the patient pathway WP5: Management / Coordination / Consortium 9 NMI/DIs: NPL (Coordinator, UK), VSL (WP1 lead, Netherlands), STUK (WP2 lead, Finland), CMI (WP3 lead, Czechia), FTMC (Lithuania), IST (Portugal), SSM (Sweden), CHUV, METAS (Switzerland). 5 clinical beneficiaries: Lund (WP4 lead, Sweden), HUS (Finland), VUHSK (Lithuania), KS (Sweden), RSFT (UK).